|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2025
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
30
April 2025 - “Haleon 2025 Q1 Trading
Statement”
|
|
30
April 2025 - “Haleon 2025 Q1 Trading
Statement”
|
99.1
Haleon plc: 2025 Q1 Trading Statement
30 April 2025: Haleon plc
(the "Company" or "Haleon") today announces its Q1
trading statement for the year ending 31 December 2025 is available
at: http://www.rns-pdf.londonstockexchange.com/rns/7068G_1-2025-4-29.pdf.
The Q1 trading statement will also be available on the Haleon
website www.haleon.com/investors,
and has been submitted in full unedited text to the Financial
Conduct Authority's National Storage Mechanism and will shortly be
available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Presentation for analysts and shareholders
A short presentation followed by Q&A will be hosted by Dawn
Allen, Chief Financial Officer at 8:30am BST (9:30am CEST) on 30
April 2025, which can be accessed at www.haleon.com/investors.
For analysts and shareholders wishing to ask questions on the
Q&A call, please use the dial-in details below which will have
a Q&A facility:
|
UK:
|
+44 800 358 1035
|
|
US:
|
+1 855 979 6654
|
|
All other:
|
+44 203 936 2999
|
|
Passcode:
|
181477
|
An archived webcast of the Q&A call will be available later on
the day of the results and can be accessed
at www.haleon.com/investors.
Amanda Mellor
Company Secretary
Enquiries
|
Investors
|
Media
|
||
|
Jo Russell
|
+44 7787 392441
|
Zoë Bird
|
+44 7736 746167
|
|
Rakesh Patel
|
+44 7552 484646
|
Victoria Durman
|
+44 7894 505730
|
|
Emma White
|
+44 7823 523562
|
|
|
|
Email: [email protected]
|
Email: [email protected]
|
||
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans five major categories - Oral Health, Pain
Relief, Respiratory Health, Digestive Health and Other, and
Vitamins, Minerals and Supplements (VMS). Its long-standing brands
- such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin,
Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
April 30, 2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|